PL3002298T3 - Przeciwciała monoklonalne anty-czynnik XI i sposoby ich zastosowania - Google Patents

Przeciwciała monoklonalne anty-czynnik XI i sposoby ich zastosowania

Info

Publication number: PL3002298T3
Authority: PL; Poland
Prior art keywords: factor; methods; monoclonal antibodies; monoclonal; antibodies
Prior art date: 2007-11-21

Application number

PL15189714T

Other languages

English (en)

Inventor

Andras Gruber

Erik Ian Tucker

Stephen Raymond Hanson

David Gailani

Original Assignee

Oregon Health & Science University

Vanderbilt University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-21

Filing date

2008-11-21

Publication date

2020-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40568500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3002298(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-11-21 Application filed by Oregon Health & Science University, Vanderbilt University filed Critical Oregon Health & Science University

2020-03-31 Publication of PL3002298T3 publication Critical patent/PL3002298T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Mycology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL15189714T 2007-11-21 2008-11-21 Przeciwciała monoklonalne anty-czynnik XI i sposoby ich zastosowania PL3002298T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US98952307P	2007-11-21	2007-11-21
EP08852770.0A EP2222707B1 (en)	2007-11-21	2008-11-21	Anti-factor xi monoclonal antibodies and methods of use thereof
PCT/US2008/084336 WO2009067660A2 (en)	2007-11-21	2008-11-21	Anti-factor xi monoclonal antibodies and methods of use thereof
EP15189714.7A EP3002298B1 (en)	2007-11-21	2008-11-21	Anti-factor xi monoclonal antibodies and methods of use thereof

Publications (1)

Publication Number	Publication Date
PL3002298T3 true PL3002298T3 (pl)	2020-03-31

Family

ID=40568500

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15189714T PL3002298T3 (pl)	2007-11-21	2008-11-21	Przeciwciała monoklonalne anty-czynnik XI i sposoby ich zastosowania

Country Status (15)

Country	Link
US (7)	US8236316B2 (pl)
EP (2)	EP2222707B1 (pl)
JP (1)	JP2011504371A (pl)
AU (1)	AU2008326348B2 (pl)
CA (1)	CA2705851C (pl)
CY (1)	CY1122270T1 (pl)
DK (2)	DK2222707T3 (pl)
ES (2)	ES2755376T3 (pl)
HR (1)	HRP20191999T1 (pl)
HU (1)	HUE046564T2 (pl)
LT (1)	LT3002298T (pl)
PL (1)	PL3002298T3 (pl)
PT (1)	PT3002298T (pl)
SI (1)	SI3002298T1 (pl)
WO (1)	WO2009067660A2 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2008326348B2 (en)	2007-11-21	2014-01-30	Oregon Health & Science University	Anti-factor XI monoclonal antibodies and methods of use thereof
HUE041556T2 (hu) *	2008-06-19	2019-05-28	Prothix Bv	XI-es faktor elleni ellenanyagok alkalmazása vérrögképzõdés megelõzésére vagy kezelésére
CN104212799B (zh)	2008-10-15	2018-11-23	Ionis制药公司	因子11表达的调节
AU2009335643B2 (en)	2008-12-18	2014-05-29	Oregon Health & Science University	Anti-fXI antibodies and methods of use
EP2419146A4 (en) *	2009-04-15	2013-11-27	Isis Pharmaceuticals Inc	MODULATION OF IGNITION REACTIONS BY FACTOR XI
SG183443A1 (en) *	2010-03-01	2012-09-27	Bayer Healthcare Llc	Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
JP6109081B2 (ja)	2011-03-09	2017-04-05	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	人工表面との接触を含む医学的手技に伴う投与のためのｆｘｉｉ阻害剤
EP2497489A1 (en) *	2011-03-09	2012-09-12	CSL Behring GmbH	Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
SI2847228T1 (sl) *	2012-05-10	2018-11-30	Bayer Pharma Aktiengesellschaft	Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe
WO2014089493A1 (en)	2012-12-07	2014-06-12	Vanderbilt University	Antibodies against factor xii and uses thereof
US20140220552A1 (en) *	2013-02-01	2014-08-07	Becton, Dickinson And Company	Blood collection devices containing contact pathway inhibition additives
US10286047B2 (en)	2013-03-08	2019-05-14	Csl Behring Gmbh	Treatment and prevention of remote ischemia-reperfusion injury
WO2016020882A2 (en)	2014-08-07	2016-02-11	Novartis Ag	Angiopoetin-like 4 (angptl4) antibodies and methods of use
SG10201805646WA (en)	2014-08-07	2018-08-30	Novartis Ag	Angiopoietin-like 4 antibodies and methods of use
JOP20200312A1 (ar) *	2015-06-26	2017-06-16	Novartis Ag	الأجسام المضادة للعامل xi وطرق الاستخدام
EP3325010B1 (en) *	2015-07-23	2023-06-21	The Regents of The University of California	Antibodies to coagulation factor xia and uses thereof
AR107505A1 (es)	2016-01-22	2018-05-09	Merck Sharp & Dohme	Anticuerpos anti-factor de la coagulación xi
US11059905B2 (en) *	2016-03-23	2021-07-13	Prothix B.V.	Monoclonal antibodies against the active site of factor XI and uses thereof
TW201802121A (zh)	2016-05-25	2018-01-16	諾華公司	抗因子XI/XIa抗體之逆轉結合劑及其用途
KR102218714B1 (ko)	2016-06-14	2021-02-24	머크 샤프 앤드 돔 코포레이션	항응고 인자 xi 항체
EP3293593B1 (en) *	2016-09-12	2019-03-20	Sandvik Intellectual Property AB	Method for estimating error propagation
DK3515947T3 (da) *	2016-09-20	2024-07-29	Aronora Inc	Hidtil ukendte antistoffer mod faktor XI og anvendelser deraf
AU2017383232B2 (en) *	2016-12-23	2024-09-12	Novartis Ag	Factor XI antibodies and methods of use
US20200231701A1 (en) *	2016-12-23	2020-07-23	Novartis Ag	Methods of treatment with anti-factor xi/xia antibodies
CN108409863B (zh) *	2017-02-10	2023-09-26	上海仁会生物制药股份有限公司	抗凝血因子xi抗体
WO2020029179A1 (en) *	2018-08-09	2020-02-13	Shanghai Benemae Pharmaceutical Corporation	Anti-factor xi antibodies
US11958911B2 (en)	2017-02-10	2024-04-16	Shanghai Benemae Pharmaceutical	Anti-coagulation factor XI antibody
WO2019102353A1 (en)	2017-11-22	2019-05-31	Novartis Ag	Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
WO2019217450A1 (en) *	2018-05-08	2019-11-14	Rhode Island Hospital	Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
US20210355497A1 (en)	2018-05-09	2021-11-18	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing fxi expression
EP3914624A4 (en)	2019-01-21	2022-10-19	Aronora, Inc.	NOVEL HUMANIZED ANTIBODIES AGAINST FACTOR XI HAVING ANTI-THROMBOTIC AND ANTI-INFLAMMATORY EFFECTS AND ASSOCIATED USES
AU2021302199A1 (en) *	2020-07-03	2023-02-23	Suzhou Alphamab Co., Ltd.	Coagulation factor XI (FXI) binding protein
WO2024141099A1 (zh) *	2022-12-30	2024-07-04	甘李药业股份有限公司	抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ201918A (en)	1981-09-18	1987-04-30	Genentech Inc	N-terminal methionyl analogues of bovine growth hormone
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0216846B2 (en)	1985-04-01	1995-04-26	Celltech Limited	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en)	1987-02-17	1989-10-10	The United States Of America As Represented By The Department Of Health And Human Services	Process for site specific mutagenesis without phenotypic selection
US5892019A (en)	1987-07-15	1999-04-06	The United States Of America, As Represented By The Department Of Health And Human Services	Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
AU631802B2 (en)	1988-06-14	1992-12-10	Cetus Oncology Corporation	Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5225538A (en)	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
ZA902949B (en)	1989-05-05	1992-02-26	Res Dev Foundation	A novel antibody delivery system for biological response modifiers
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
DE69133566T2 (de)	1990-01-12	2007-12-06	Amgen Fremont Inc.	Bildung von xenogenen Antikörpern
US5314995A (en)	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en)	1990-03-20	1991-10-03	The Trustees Of Columbia University In The City Of New York	Chimeric antibodies with receptor binding ligands in place of their constant region
ATE218889T1 (de)	1990-11-09	2002-06-15	Stephen D Gillies	Cytokine immunokonjugate
FR2686087A1 (fr)	1992-01-13	1993-07-16	Inst Nat Sante Rech Med	Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5877289A (en) *	1992-03-05	1999-03-02	The Scripps Research Institute	Tissue factor compositions and ligands for the specific coagulation of vasculature
US20030235587A1 (en)	1998-08-07	2003-12-25	Feuerstein Giora Z.	Anticoagulant agents useful in treatment of thrombosis
GB9701425D0 (en)	1997-01-24	1997-03-12	Bioinvent Int Ab	A method for in vitro molecular evolution of protein function
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US6623960B1 (en) *	1999-02-12	2003-09-23	The United States Of America As Represented By The Department Of Health And Human Services	Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19
US6849425B1 (en)	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
CA2411369A1 (en) *	2000-05-15	2001-11-22	Smithkline Beecham Corporation	Antithrombotic agents
AU2001297872B2 (en)	2000-11-17	2006-11-09	University Of Rochester	In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002096948A2 (en)	2001-01-29	2002-12-05	Idec Pharmaceuticals Corporation	Engineered tetravalent antibodies and methods of use
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20080138837A1 (en) *	2004-07-19	2008-06-12	Robert Greenfield	Methods and kits for detecting and measuring ADAMTS13/FXI complexes
WO2006055178A2 (en) *	2004-10-25	2006-05-26	Merck & Co., Inc.	Anti-addl antibodies and uses thereof
US7859456B2 (en)	2006-10-10	2010-12-28	Sirf Technology Holdings, Inc.	Method of mixed data assisted and non data assisted navigation signal acquisition, tracking and reacquisition
CA2685015A1 (en) *	2007-04-23	2008-11-06	Schering Corporation	Anti-mdl-1 antibodies
AU2008326348B2 (en)	2007-11-21	2014-01-30	Oregon Health & Science University	Anti-factor XI monoclonal antibodies and methods of use thereof
HUE041556T2 (hu)	2008-06-19	2019-05-28	Prothix Bv	XI-es faktor elleni ellenanyagok alkalmazása vérrögképzõdés megelõzésére vagy kezelésére
AU2009322836B2 (en)	2008-11-25	2013-04-04	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
KR20140019004A (ko)	2010-05-27	2014-02-13	머크 샤프 앤드 돔 코포레이션	가용성 구아닐레이트 시클라제 활성화제
EP2585055A1 (de)	2010-06-25	2013-05-01	Bayer Intellectual Property GmbH	Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
CN103097387B (zh)	2010-07-09	2016-11-02	拜耳知识产权有限责任公司	环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途
DE102010040233A1 (de)	2010-09-03	2012-03-08	Bayer Schering Pharma Aktiengesellschaft	Bicyclische Aza-Heterocyclen und ihre Verwendung
US20140171434A1 (en)	2011-01-11	2014-06-19	Bayer Pharma Aktiengessellschaft	Substituted imidazopyridines and imidazopyridazines and the use thereof
CN103619845B (zh)	2011-04-21	2016-08-17	拜耳知识产权有限责任公司	氟烷基取代的吡唑并吡啶及其用途
CA2844730A1 (en)	2011-09-01	2013-03-07	F. Hoffmann-La Roche Ag	Pyrrolopyrazine kinase inhibitors
JP6054967B2 (ja)	2011-09-02	2016-12-27	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	置換アネレート化ピリミジンおよびその使用
SI2847228T1 (sl)	2012-05-10	2018-11-30	Bayer Pharma Aktiengesellschaft	Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe

2008
- 2008-11-21 AU AU2008326348A patent/AU2008326348B2/en not_active Ceased
- 2008-11-21 ES ES15189714T patent/ES2755376T3/es active Active
- 2008-11-21 LT LT15189714T patent/LT3002298T/lt unknown
- 2008-11-21 DK DK08852770.0T patent/DK2222707T3/en active
- 2008-11-21 SI SI200832100T patent/SI3002298T1/sl unknown
- 2008-11-21 PT PT151897147T patent/PT3002298T/pt unknown
- 2008-11-21 JP JP2010535088A patent/JP2011504371A/ja not_active Withdrawn
- 2008-11-21 WO PCT/US2008/084336 patent/WO2009067660A2/en not_active Ceased
- 2008-11-21 EP EP08852770.0A patent/EP2222707B1/en not_active Not-in-force
- 2008-11-21 PL PL15189714T patent/PL3002298T3/pl unknown
- 2008-11-21 DK DK15189714T patent/DK3002298T3/da active
- 2008-11-21 ES ES08852770.0T patent/ES2566963T3/es active Active
- 2008-11-21 US US12/744,037 patent/US8236316B2/en active Active
- 2008-11-21 HU HUE15189714A patent/HUE046564T2/hu unknown
- 2008-11-21 EP EP15189714.7A patent/EP3002298B1/en not_active Revoked
- 2008-11-21 CA CA2705851A patent/CA2705851C/en not_active Expired - Fee Related
2012
- 2012-04-13 US US13/446,320 patent/US8399648B2/en active Active
2013
- 2013-03-04 US US13/783,952 patent/US20130171144A1/en not_active Abandoned
2014
- 2014-04-01 US US14/242,692 patent/US9125895B2/en active Active
2015
- 2015-07-27 US US14/809,551 patent/US9636399B2/en active Active
2017
- 2017-03-27 US US15/470,758 patent/US20170204195A1/en not_active Abandoned
2018
- 2018-07-30 US US16/049,141 patent/US10577428B2/en active Active
2019
- 2019-11-05 HR HRP20191999TT patent/HRP20191999T1/hr unknown
- 2019-11-06 CY CY20191101163T patent/CY1122270T1/el unknown

Also Published As

Publication number	Publication date
LT3002298T (lt)	2019-12-10
CA2705851A1 (en)	2009-05-28
WO2009067660A3 (en)	2009-07-09
SI3002298T1 (sl)	2019-12-31
EP3002298B1 (en)	2019-08-28
AU2008326348A1 (en)	2009-05-28
HRP20191999T1 (hr)	2020-02-07
DK3002298T3 (da)	2019-10-28
US20180355057A1 (en)	2018-12-13
EP2222707A2 (en)	2010-09-01
US20140322219A1 (en)	2014-10-30
US9125895B2 (en)	2015-09-08
EP2222707B1 (en)	2016-01-06
CA2705851C (en)	2016-11-01
US20150322163A1 (en)	2015-11-12
US9636399B2 (en)	2017-05-02
US20170204195A1 (en)	2017-07-20
AU2008326348B2 (en)	2014-01-30
ES2755376T3 (es)	2020-04-22
WO2009067660A2 (en)	2009-05-28
US8399648B2 (en)	2013-03-19
US10577428B2 (en)	2020-03-03
US20120276112A1 (en)	2012-11-01
JP2011504371A (ja)	2011-02-10
US8236316B2 (en)	2012-08-07
US20130171144A1 (en)	2013-07-04
HK1223114A1 (en)	2017-07-21
PT3002298T (pt)	2019-11-20
DK2222707T3 (en)	2016-04-11
EP3002298A1 (en)	2016-04-06
HUE046564T2 (hu)	2020-03-30
CY1122270T1 (el)	2020-11-25
US20110020349A1 (en)	2011-01-27
ES2566963T3 (es)	2016-04-18

Publication	Publication Date	Title
LT3002298T (lt)	2019-12-10	Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai
IL266039A (en)	2019-06-30	Anti-factor D antibodies of human origin and their uses
HRP20181969T1 (hr)	2019-02-08	Humanizirana protutijela protiv čimbenika d i njihova upotreba
EP2021029A4 (en)	2010-01-06	HUMANIZED FC RIB SPECIFIC ANTIBODIES AND METHOD FOR THEIR USE
IL200610A0 (en)	2010-05-17	Human monoclonal anti-ip-10 antibodies and uses thereof
PL2594586T3 (pl)	2015-02-27	Przeciwciała monoklonalne IL-31 i sposoby ich zastosowania
IL195573A0 (en)	2011-08-01	Fc??RIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP2347038A4 (en)	2013-06-12	METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
IL248723B (en)	2018-03-29	Specific antibodies against the bcr complex and methods of using them
PT2373691T (pt)	2019-05-08	Anticorpos anti-fxi e métodos de utilização
EP2104513A4 (en)	2011-05-25	OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE
EP2185719A4 (en)	2012-01-04	RANTES ANTIBODIES AND METHOD FOR THEIR USE
IL211623A0 (en)	2011-05-31	Anti-notch2 antibodies and methods of use
EP2077325A4 (en)	2012-04-11	MONOCLONAL ANTIBODY AND ITS USE
EP2540742A4 (en)	2014-02-12	MONOCLONAL ANTIBODIES OF ANTI-CYR61 PROTEIN AND USES THEREOF